While cancer continues to be one of the leading causes of death and illness, new technology and increasing use of real-world data have the potential to revolutionise care.
NICE has recommended regular NHS funding for Takeda’s Adcetris in an aggressive type of non-Hodgkin lymphoma after the company submitted further data to support its case.